17
Sep 24
The Italian Council of State upholds the Competition Authority’s €3.2M fine for abuse of dominance by negotiating an unjustifiably high reimbursement price for an “orphan” drug (Leadiant Biosciences)
With judgement No. 2967 of March 29, 2024, The Council of State [1] (Italy’s top administrative court) upheld a fine against the pharmaceutical group Leadiant (“Leadiant”) by the Italian Competition Authority (the AGCM or the “ICA”) for abuse of a dominant position pursuant to Article 102 of the Treaty on the Functioning of the European Union (TFEU).
1
Jul 24
Pfizer ordered to pay damages to the National Health System for abusing a dominant position in managing the Xalatan patent lifecycle
From 2012 to 2014, Pfizer Italia S.r.l., Pfizer Health A.B., and Pfizer Inc. and Ratiopharm Italia S.r.l. locked horns in litigation before the AGCM and the Italian administrative court.
5
Dec 22
The European Commission sends a Statement of Objection to a drug manufacturer accusing it of regulatory gaming and denigration of competitors in breach of Article 102 TFEU
On October 10, 2022, the European Commission sent a Statement of Objection to Teva accusing the company of denigrating a competing product and of “regulatory gaming” in management of the life cycle of its multiple sclerosis drug Capoxone, conduct deemed abusive pursuant to Article 102 of the Treaty on the Functioning of the European Union.
15
Oct 20
Italian Competition Authority says that the rules on the remuneration of health care services provided by pharmacies are anti-competitive
The Italian Competition Authority once again criticizes the introduction of legislative provisions that reserve only to pharmacies the provision of certain public health services paid by the NHS
